- Previous Close
16.24 - Open
16.20 - Bid --
- Ask --
- Day's Range
16.20 - 16.20 - 52 Week Range
12.78 - 47.99 - Volume
7 - Avg. Volume
124 - Market Cap (intraday)
800.758M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.38 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
www.staar.com1,157
Full Time Employees
December 27
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: SR3.F
View MorePerformance Overview: SR3.F
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SR3.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SR3.F
View MoreValuation Measures
Market Cap
802.48M
Enterprise Value
625.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.75
Price/Book (mrq)
2.18
Enterprise Value/Revenue
2.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.44%
Return on Assets (ttm)
-1.55%
Return on Equity (ttm)
-5.16%
Revenue (ttm)
313.9M
Net Income Avi to Common (ttm)
-20.21M
Diluted EPS (ttm)
-0.38
Balance Sheet and Cash Flow
Total Cash (mrq)
230.49M
Total Debt/Equity (mrq)
9.75%
Levered Free Cash Flow (ttm)
15.79M